Hepatitis E epidemiology and demographics: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
Line 4: Line 4:


==Overview==
==Overview==
An estimated 20 million infections and 3.3 million acute cases occur annually worldwide with an estimated 56 600 deaths.<ref name=WHO>{{cite web | title = Hepatitis E | url = http://www.who.int/mediacentre/factsheets/fs280/en/ }}</ref>
An estimated 20 million infections and 3.3 million acute cases occur annually worldwide with an estimated 56 600 deaths.<ref name=WHO>{{cite web | title = Hepatitis E | url = http://www.who.int/mediacentre/factsheets/fs280/en/ }}</ref>  [[HEV]] displays different epidemiological and clinical characteristics between developing and developed countries.<ref name=CDC>{{cite web | title = Hepatitis E Epidemiology | url = http://wwwnc.cdc.gov/travel/yellowbook/2014/chapter-3-infectious-diseases-related-to-travel/hepatitis-e }}</ref>
==Prevalence==
==Prevalence==
In the United States, the seroprevalence of hepatitis E is 21%. <ref name="pmid22549046">{{cite journal| author=Kamar N, Bendall R, Legrand-Abravanel F, Xia NS, Ijaz S, Izopet J et al.| title=Hepatitis E. | journal=Lancet | year= 2012 | volume= 379 | issue= 9835 | pages= 2477-88 | pmid=22549046 | doi=10.1016/S0140-6736(11)61849-7 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=22549046  }} </ref>
In the United States, the seroprevalence of hepatitis E is 21%. <ref name="pmid22549046">{{cite journal| author=Kamar N, Bendall R, Legrand-Abravanel F, Xia NS, Ijaz S, Izopet J et al.| title=Hepatitis E. | journal=Lancet | year= 2012 | volume= 379 | issue= 9835 | pages= 2477-88 | pmid=22549046 | doi=10.1016/S0140-6736(11)61849-7 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=22549046  }} </ref>

Revision as of 00:15, 28 August 2014

Hepatitis E Microchapters

Home

Patient Information

Overview

Historical Perspective

Pathophysiology

Causes

Epidemiology and Demographics

Risk Factors

Screening

Differentiating Hepatitis E from other Diseases

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Treatment

Medical Therapy

Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Hepatitis E epidemiology and demographics On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Hepatitis E epidemiology and demographics

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Hepatitis E epidemiology and demographics

CDC on Hepatitis E epidemiology and demographics

Hepatitis E epidemiology and demographics in the news

Blogs on Hepatitis E epidemiology and demographics

Directions to Hospitals Treating Hepatitis E

Risk calculators and risk factors for Hepatitis E epidemiology and demographics

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: João André Alves Silva, M.D. [2]

Overview

An estimated 20 million infections and 3.3 million acute cases occur annually worldwide with an estimated 56 600 deaths.[1] HEV displays different epidemiological and clinical characteristics between developing and developed countries.[2]

Prevalence

In the United States, the seroprevalence of hepatitis E is 21%. [3]

Adapted from Center for Disease Control and Prevention(CDC)[2]

Incidence

The estimated annual incidence of hepatitis E in the United States is 700 per 100,000 (0.7%) of the overall population.[4]

Age

Clinical manifestations of hepatitis E are highest in young adults aged 15 to 49 years.[2] The rate of anti-HEV antibodies increases with age. According to a survey conducted in the US from 1988 to 1994, this rate can range from 10% (6 to 10 years) to 40% (>60 years).[5]

Gender

Women have a minimally smaller rate of anti-HEV antibodies (20.4%) than men (21.6%).[3]

Pregnant Women

Although pregnant women have the same exposure to the virus as other people, due to their micronutrient status and cytokine levels, they are more prone to the severe form of the disease. [6]

In outbreak-prone areas pregnant women (whether infected sporadically or during an epidemic) are at risk of progressing to liver failure and death after infection. Miscarriages and neonatal death also commonly occur as a result of HEV infection.[2]

Race

After adjusting to age, the rate of anti-HEV antibodies was noted to be higher in non-hispanic whites (22.1%) than among blacks (14.5%).[5]

Developed Countries

Small outbreaks and individuals cases of hepatitis E are often related to consumption of undercook pork, shellfish, as well as to blood transfusions.[6][7][8][9] The rate of anti-HEV antibodies is lower than in developing countries. [6]

Developing Countries

Hepatitis E may occur either as a sporadic case, or as an epidemic disease. It is often caused by genotypes 1 (Asia) and 2 (Central America and Africa).[10] Anti-HEV antibodies were detected in 30 to 80% of adults.[6]

The highest seroprevalence rates is observed in regions where low standards of sanitation increase the risk for transmission of the virus. Over 60% of all HEV infections and 65% of all hepatitis E deaths occur in East and South Asia, where seroprevalence rates of 25% are common in some age groups. In Egypt, half the population aged above five years is serologically positive for the hepatitis E virus.[1]

Men in developing countries manifest symptoms of hepatitis E 2 to 5 times more than women during outbreaks.[11][12]

References

  1. 1.0 1.1 "Hepatitis E".
  2. 2.0 2.1 2.2 2.3 "Hepatitis E Epidemiology".
  3. 3.0 3.1 Kamar N, Bendall R, Legrand-Abravanel F, Xia NS, Ijaz S, Izopet J; et al. (2012). "Hepatitis E." Lancet. 379 (9835): 2477–88. doi:10.1016/S0140-6736(11)61849-7. PMID 22549046.
  4. Kantala T, Maunula L, von Bonsdorff CH, Peltomaa J, Lappalainen M (2009). "Hepatitis E virus in patients with unexplained hepatitis in Finland". J Clin Virol. 45 (2): 109–13. doi:10.1016/j.jcv.2009.03.006. PMID 19376741.
  5. 5.0 5.1 Kuniholm MH, Purcell RH, McQuillan GM, Engle RE, Wasley A, Nelson KE (2009). "Epidemiology of hepatitis E virus in the United States: results from the Third National Health and Nutrition Examination Survey, 1988-1994". J Infect Dis. 200 (1): 48–56. doi:10.1086/599319. PMC 2762746. PMID 19473098.
  6. 6.0 6.1 6.2 6.3 Hoofnagle JH, Nelson KE, Purcell RH (2012). "Hepatitis E." N Engl J Med. 367 (13): 1237–44. doi:10.1056/NEJMra1204512. PMID 23013075.
  7. Boxall E, Herborn A, Kochethu G, Pratt G, Adams D, Ijaz S; et al. (2006). "Transfusion-transmitted hepatitis E in a 'nonhyperendemic' country". Transfus Med. 16 (2): 79–83. doi:10.1111/j.1365-3148.2006.00652.x. PMID 16623913.
  8. Matsubayashi K, Kang JH, Sakata H, Takahashi K, Shindo M, Kato M; et al. (2008). "A case of transfusion-transmitted hepatitis E caused by blood from a donor infected with hepatitis E virus via zoonotic food-borne route". Transfusion. 48 (7): 1368–75. doi:10.1111/j.1537-2995.2008.01722.x. PMID 18651907.
  9. Wichmann O, Schimanski S, Koch J, Kohler M, Rothe C, Plentz A; et al. (2008). "Phylogenetic and case-control study on hepatitis E virus infection in Germany". J Infect Dis. 198 (12): 1732–41. doi:10.1086/593211. PMID 18983248.
  10. Purcell RH, Emerson SU (2008). "Hepatitis E: an emerging awareness of an old disease". J Hepatol. 48 (3): 494–503. doi:10.1016/j.jhep.2007.12.008. PMID 18192058.
  11. Zhuang H, Cao XY, Liu CB, Wang GM (1991). "Epidemiology of hepatitis E in China". Gastroenterol Jpn. 26 Suppl 3: 135–8. PMID 1909252.
  12. Aggarwal R, Kumar R, Pal R, Naik S, Semwal SN, Naik SR (2002). "Role of travel as a risk factor for hepatitis E virus infection in a disease-endemic area". Indian J Gastroenterol. 21 (1): 14–8. PMID 11871830.